1. Gomi H, Solomkin JS, et al. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2018;25(1):3-16.
2. Gomi H, Takada T, et al. Updated comprehensive epidemiology, microbiology, and outcomes among patients with acute cholangitis. J Hepatobiliary Pancreat Sci. 2017;24:310–8.
3. Gomi H, Solomkin JS, et al. TG13 antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2013;20:60–70.
4. Sung YK, Lee JK, et al. The Clinical epidemiology and outcomes of bacteremic biliary tract infections caused by antimicrobial‐resistant pathogens. Am J Gastroenterol. 2012;107:473–83.
5. Peirano G, van der Bij AK, et al. Molecular epidemiology over an 11‐year Period (2000 to 2010) of extended‐Spectrum β‐lactamase‐producing Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol. 2012;50:294–9.
6. Mazuski JE, Tessier JM, et al. The Surgical Infection Society Revised Guidelines on the Management of Intra‐Abdominal Infection. Surgical infections. 2017;18:1–76.
7. Coccolini F, Sartelli M, et al. Antibiotic resistance pattern and clinical outcomes in acute cholecystitis: 567 consecutive worldwide patients in a prospective cohort study. Int J Surg. 2015;21:32–7.
8. Reuken PA, Torres D, et al. Risk factors for multi‐drug resistant pathogens and failure of empiric first‐line therapy in acute cholangitis. PLoS One. 2017;12:1–12.
9. Kwon JS, Han J, et al. Changes in causative pathogens of acute cholangitis and their antimicrobial susceptibility over a period of 6 years. Korean J. Gastroenterol. 2014;63:299–307.
10. Shenoy S, Shenoy S, et al. Clinicomicrobiological analysis of patients with cholangitis. Indian J Med Microbiol. 2014;32:157.
11. Goo JC, Seong MH, et al. Extended Spectrum‐β‐Lactamase or Carbapenemase Producing bacteria isolated from patients with acute cholangitis. Clin Endosc. 2012;45:155–60.
12. Kiriyama S, Kozaka K, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2018;25:17–30.
13. Goldstein EJ, Solomkin JS, et al. Clinical efficacy and correlation of clinical outcomes with In Vitro susceptibility for anaerobic bacteria in patients with complicated intra‐abdominal infections treated with moxifloxacin. Clin Infect Dis. 2011;53:1074–80.
14. Buckman SA, Mazuski JE. Review of the Tokyo Guidelines 2018: Antimicrobial Therapy for Acute Cholangitis and Cholecystitis. JAMA Surg. 2019;154(9):873–874
15. Tanaka A, Takada T, et al. Antimicrobial therapy for acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007;14:59–67.
16. Yoshida M, Takada T, et al. Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007;14:83–90.
17. Rhodes A, Evans LE, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43:304–77.
18. Solomkin JS, Mazuski JE, et al. Diagnosis and management of complicated Intra‐abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:133–64.
19. Gomi H, Solomkin JS, et al. TG13 antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2013;20:60–70.
20. Pisano, M., Allievi, N., et al. 2020 World Society of Emergency Surgery updated guidelines for the diagnosis and treatment of acute calculus cholecystitis. World J Emerg Surg 15, 61. 2020. https://doi.org/10.1186/s13017-020-00336-x